Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Endocrinology and Metabolic Disease | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Interferons | 1 |
Target |
Mechanism ROCK1 inhibitors [+1] |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date16 Jul 2021 |
Target |
Mechanism IFNAR agonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date06 Oct 1997 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Dec 2006 |
Sponsor / Collaborator Yale University [+3] |
Start Date01 Oct 2003 |
Sponsor / Collaborator |
Start Date01 Feb 2002 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Belumosudil ( ROCK1 x ROCK2 ) | Chronic graft-versus-host disease More | Approved |
INTERFERON ALFACON-1 ( IFNAR ) | Hepatitis C More | Approved |
KD-026 ( MTTP ) | Diabetes Mellitus, Type 2 More | Phase 2 |
YIV-906 | Pancreatic Cancer More | Discontinued |
Salirasib ( Ras ) | Colorectal Cancer More | Discontinued |